Advances in systemic therapy for gastroenteropancreatic neuroendocrine malignancies

Thorvardur R. Halfdanarson, Jonathan R. Strosberg

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Neuroendocrine tumors (NETs) are relatively uncommon. They typically arise in the gastrointestinal tract and lungs, and their incidence seems to be rising. Most patients have advanced disease at the time of diagnosis and many more will relapse after surgery. There is thus a great need for improvements in therapy for advanced neuroendocrine tumors. This article reviews the current therapy for both pancreatic NETs and non-pancreatic gastrointestinal NETs, and discusses recent advances in NET management with an emphasis on targeted therapy.

Original languageEnglish (US)
Pages (from-to)305-310
Number of pages6
JournalCurrent Clinical Pharmacology
Issue number4
StatePublished - 2015


  • Carcinoid tumors
  • Neuroendocrine tumors
  • Targeted therapy
  • Therapy

ASJC Scopus subject areas

  • General Pharmacology, Toxicology and Pharmaceutics
  • Pharmacology (medical)


Dive into the research topics of 'Advances in systemic therapy for gastroenteropancreatic neuroendocrine malignancies'. Together they form a unique fingerprint.

Cite this